Tipifarnib Targets HRAS-Mutant Cancers.

Abstract

Tipifarnib may be effective in treating HRAS-mutant head and neck squamous cell carcinoma. In a phase II trial, the drug elicited responses in 10 of 18 patients with HRAS mutations at a variant allele frequency of at least 20%, and responders had a median progression-free survival of 8.3 months.